Novel |
PDCD6 |
programmed cell death 6 |
|
- Calcium
- Zinc
- Calcium citrate
- Calcium Phosphate
- Calcium phosphate dihydrate
- Zinc acetate
|
|
Novel |
IRS1 |
insulin receptor substrate 1 |
- PI3K Cascade
- IRS-mediated signalling
- SOS-mediated signalling
- SOS-mediated signalling
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- PI3K/AKT activation
- PI3K/AKT activation
- Constitutive Signaling by Aberrant PI3K in Cancer
- IRS-related events triggered by IGF1R
- Signaling by Leptin
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- IRS activation
- Signal attenuation
- Activated NTRK3 signals through PI3K
- Growth hormone receptor signaling
|
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
|
|
Novel |
NDUFS6 |
NADH:ubiquinone oxidoreductase subunit S6 |
- Respiratory electron transport
- Complex I biogenesis
|
|
- Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
|
Novel |
ATPAF2 |
ATP synthase mitochondrial F1 complex assembly factor 2 |
|
|
- Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
|
Novel |
EXOC3 |
exocyst complex component 3 |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Insulin processing
- VxPx cargo-targeting to cilium
|
|
|
Novel |
HMGB2 |
high mobility group box 2 |
- Apoptosis induced DNA fragmentation
|
|
|
Novel |
ICE1 |
interactor of little elongation complex ELL subunit 1 |
- RNA polymerase II transcribes snRNA genes
- RNA polymerase II transcribes snRNA genes
|
|
|
Novel |
IFT57 |
intraflagellar transport 57 |
- Hedgehog 'off' state
- Intraflagellar transport
- Intraflagellar transport
|
|
|
Novel |
PTMA |
prothymosin alpha |
|
|
|
|
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
- Signaling by ERBB2
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- vRNP Assembly
- Regulation of actin dynamics for phagocytic cup formation
- eNOS activation
- Regulation of PLK1 Activity at G2/M Transition
- Scavenging by Class F Receptors
- Scavenging by Class F Receptors
- HSP90 chaperone cycle for steroid hormone receptors (SHR)
- HSF1 activation
- Attenuation phase
- HSF1-dependent transactivation
- Loss of Nlp from mitotic centrosomes
- Recruitment of mitotic centrosome proteins and complexes
- Loss of proteins required for interphase microtubule organization from the centrosome
- Recruitment of NuMA to mitotic centrosomes
- Sema3A PAK dependent Axon repulsion
- VEGFA-VEGFR2 Pathway
- VEGFA-VEGFR2 Pathway
- VEGFR2 mediated vascular permeability
- Uptake and function of diphtheria toxin
- PIWI-interacting RNA (piRNA) biogenesis
- Anchoring of the basal body to the plasma membrane
- Constitutive Signaling by EGFRvIII
- Regulation of necroptotic cell death
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
- The role of GTSE1 in G2/M progression after G2 checkpoint
- AURKA Activation by TPX2
- Downregulation of ERBB2 signaling
- ESR-mediated signaling
- Extra-nuclear estrogen signaling
- RHOBTB2 GTPase cycle
- Estrogen-dependent gene expression
- Chaperone Mediated Autophagy
- Constitutive Signaling by Overexpressed ERBB2
- Aggrephagy
- Drug-mediated inhibition of ERBB2 signaling
- Signaling by ERBB2 KD Mutants
- Resistance of ERBB2 KD mutants to trastuzumab
- Resistance of ERBB2 KD mutants to sapitinib
- Resistance of ERBB2 KD mutants to tesevatinib
- Resistance of ERBB2 KD mutants to neratinib
- Resistance of ERBB2 KD mutants to osimertinib
- Resistance of ERBB2 KD mutants to afatinib
- Resistance of ERBB2 KD mutants to AEE788
- Resistance of ERBB2 KD mutants to lapatinib
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Drug resistance in ERBB2 TMD/JMD mutants
- Potential therapeutics for SARS
|
- Rifabutin
- Nedocromil
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
- Geldanamycin
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
- 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
- 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
- 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
- 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
- 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
- Quercetin
- 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
- 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
- N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- Tanespimycin
- SNX-5422
- N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
- 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
- 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
- 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
- 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
- (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
- 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
- 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
- N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
- 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
- 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
- CCT-018159
- 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
- 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
- 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
- (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
- 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
- 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
- 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
- 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
- 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
- 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
- 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
- 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
- Copper
- Polaprezinc
- Alvespimycin
|
|
|
SRC |
SRC proto-oncogene, non-receptor tyrosine kinase |
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric acid
- Paratoulene phosphate
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Tirbanibulin
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- PD-168393
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- PP-121
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
- Fostamatinib
|
|
|
ABL1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
- Regulation of actin dynamics for phagocytic cup formation
- Role of ABL in ROBO-SLIT signaling
- Role of ABL in ROBO-SLIT signaling
- Myogenesis
- Myogenesis
- RHO GTPases Activate WASPs and WAVEs
- HDR through Single Strand Annealing (SSA)
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Cyclin D associated events in G1
- RUNX1 regulates transcription of genes involved in differentiation of HSCs
- RUNX2 regulates osteoblast differentiation
- FCGR3A-mediated phagocytosis
- Factors involved in megakaryocyte development and platelet production
|
- ATP
- Imatinib
- Dasatinib
- N-[4-Methyl-3-[[4-(3-Pyridinyl)-2-Pyrimidinyl]Amino]Phenyl]-3-Pyridinecarboxamide
- Nilotinib
- XL228
- Bosutinib
- 2-{[(6-OXO-1,6-DIHYDROPYRIDIN-3-YL)METHYL]AMINO}-N-[4-PROPYL-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 1-[4-(PYRIDIN-4-YLOXY)PHENYL]-3-[3-(TRIFLUOROMETHYL)PHENYL]UREA
- Myristic acid
- PD-166326
- 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE
- 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide
- Regorafenib
- Ponatinib
- Fostamatinib
- Brigatinib
- Radotinib
|
- Chronic myeloid leukemia (CML)
- Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
|
|
MET |
MET proto-oncogene, receptor tyrosine kinase |
- PIP3 activates AKT signaling
- Constitutive Signaling by Aberrant PI3K in Cancer
- Sema4D mediated inhibition of cell attachment and migration
- RAF/MAP kinase cascade
- MET Receptor Activation
- Negative regulation of MET activity
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates RAS signaling
- MET activates PI3K/AKT signaling
- MET activates PTPN11
- MET activates PTK2 signaling
- InlB-mediated entry of Listeria monocytogenes into host cell
- InlB-mediated entry of Listeria monocytogenes into host cell
- MET interacts with TNS proteins
- MET activates RAP1 and RAC1
- MET receptor recycling
- MET activates STAT3
- MECP2 regulates neuronal receptors and channels
|
- K-252a
- SGX-523
- 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide
- N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide
- 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide
- N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide
- 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol
- AMG-208
- 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE
- Crizotinib
- Cabozantinib
- Capmatinib
- Fostamatinib
- Tivantinib
- Brigatinib
- Amuvatinib
|
- Renal cell carcinoma
- Cholangiocarcinoma
- Gastric cancer
|
|
PDGFRA |
platelet derived growth factor receptor alpha |
- PIP3 activates AKT signaling
- Downstream signal transduction
- Signaling by PDGF
- Constitutive Signaling by Aberrant PI3K in Cancer
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Imatinib-resistant PDGFR mutants
- Sunitinib-resistant PDGFR mutants
- Regorafenib-resistant PDGFR mutants
- Sorafenib-resistant PDGFR mutants
- PDGFR mutants bind TKIs
|
- Becaplermin
- Imatinib
- Sunitinib
- XL820
- Olaratumab
- Pazopanib
- Midostaurin
- Regorafenib
- Ponatinib
- Lenvatinib
- Nintedanib
- Foreskin keratinocyte (neonatal)
- Fostamatinib
- Erdafitinib
- Amuvatinib
- Ripretinib
|
|
|
BRAF |
B-Raf proto-oncogene, serine/threonine kinase |
- Spry regulation of FGF signaling
- Frs2-mediated activation
- Frs2-mediated activation
- ARMS-mediated activation
- Signalling to p38 via RIT and RIN
- RAF activation
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by MRAS-complex mutants
|
- Sorafenib
- XL281
- RAF-265
- PLX-4720
- N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide
- (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime
- Vemurafenib
- Regorafenib
- Dabrafenib
- Encorafenib
- Fostamatinib
- Ripretinib
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
- Thyroid cancer
- Malignant melanoma
|
|
PRKCA |
protein kinase C alpha |
- Calmodulin induced events
- Disinhibition of SNARE formation
- SHC1 events in ERBB2 signaling
- Signaling by SCF-KIT
- Regulation of KIT signaling
- EGFR Transactivation by Gastrin
- Inactivation, recovery and regulation of the phototransduction cascade
- Syndecan interactions
- Acetylcholine regulates insulin secretion
- Ca2+ pathway
- Trafficking of GluR2-containing AMPA receptors
- G alpha (z) signalling events
- Depolymerisation of the Nuclear Lamina
- HuR (ELAVL1) binds and stabilizes mRNA
- WNT5A-dependent internalization of FZD4
- VEGFR2 mediated cell proliferation
- RHO GTPases Activate NADPH Oxidases
- Response to elevated platelet cytosolic Ca2+
- RET signaling
- ROBO receptors bind AKAP5
- ROBO receptors bind AKAP5
|
- Phosphatidyl serine
- Vitamin E
- Tamoxifen
- Ingenol mebutate
- Aprinocarsen
- Midostaurin
- Perifosine
- Ellagic acid
- Bryostatin 1
- alpha-Tocopherol succinate
- D-alpha-Tocopherol acetate
|
|
|
AKT1 |
AKT serine/threonine kinase 1 |
- Activation of BAD and translocation to mitochondria
- PIP3 activates AKT signaling
- PIP3 activates AKT signaling
- Downregulation of ERBB2:ERBB3 signaling
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
- MTOR signalling
- AKT phosphorylates targets in the cytosol
- AKT phosphorylates targets in the cytosol
- AKT phosphorylates targets in the nucleus
- Negative regulation of the PI3K/AKT network
- eNOS activation
- AKT-mediated inactivation of FOXO1A
- Integrin signaling
- Deactivation of the beta-catenin transactivating complex
- CD28 dependent PI3K/Akt signaling
- CTLA4 inhibitory signaling
- G beta:gamma signalling through PI3Kgamma
- Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA
- KSRP (KHSRP) binds and destabilizes mRNA
- VEGFR2 mediated vascular permeability
- TP53 Regulates Metabolic Genes
- Constitutive Signaling by AKT1 E17K in Cancer
- Interleukin-4 and Interleukin-13 signaling
- Regulation of TP53 Degradation
- Regulation of TP53 Activity through Acetylation
- Regulation of TP53 Activity through Association with Co-factors
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Cyclin E associated events during G1/S transition
- Cyclin A:Cdk2-associated events at S phase entry
- PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
- RAB GEFs exchange GTP for GDP on RABs
- RUNX2 regulates genes involved in cell migration
- Regulation of PTEN stability and activity
- Extra-nuclear estrogen signaling
- Negative regulation of NOTCH4 signaling
- FLT3 Signaling
- Regulation of localization of FOXO transcription factors
- Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
- ATP
- Arsenic trioxide
- Genistein
- Inositol 1,3,4,5-Tetrakisphosphate
- Resveratrol
- Archexin
- Enzastaurin
- Perifosine
- N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
- 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
|
- PTEN hamartoma tumor syndrome (PHTS), including: Cowden syndrome; Bannayan-Riley-Ruvalcaba syndrome; Proteus syndrome; Proteus-like syndrome
|
|
MTOR |
mechanistic target of rapamycin kinase |
- PIP3 activates AKT signaling
- Macroautophagy
- MTOR signalling
- mTORC1-mediated signalling
- HSF1-dependent transactivation
- Energy dependent regulation of mTOR by LKB1-AMPK
- CD28 dependent PI3K/Akt signaling
- VEGFR2 mediated vascular permeability
- TP53 Regulates Metabolic Genes
- Constitutive Signaling by AKT1 E17K in Cancer
- Regulation of TP53 Degradation
- Regulation of PTEN gene transcription
- Amino acids regulate mTORC1
|
- Pimecrolimus
- Sirolimus
- Everolimus
- Rimiducid
- SF1126
- XL765
- Ridaforolimus
- Temsirolimus
- Fostamatinib
|
|
|
RAF1 |
Raf-1 proto-oncogene, serine/threonine kinase |
- Stimuli-sensing channels
- Rap1 signalling
- GP1b-IX-V activation signalling
- CD209 (DC-SIGN) signaling
- RAF activation
- MAP2K and MAPK activation
- Negative feedback regulation of MAPK pathway
- Negative regulation of MAPK pathway
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by MRAS-complex mutants
|
- Sorafenib
- LErafAON
- XL281
- iCo-007
- Cholecystokinin
- Regorafenib
- Dabrafenib
- Fostamatinib
|
|
|
PPIA |
peptidylprolyl isomerase A |
- Platelet degranulation
- Uncoating of the HIV Virion
- Budding and maturation of HIV virion
- Integration of provirus
- Early Phase of HIV Life Cycle
- Minus-strand DNA synthesis
- Plus-strand DNA synthesis
- Binding and entry of HIV virion
- Assembly Of The HIV Virion
- APOBEC3G mediated resistance to HIV-1 infection
- Calcineurin activates NFAT
- Basigin interactions
- Neutrophil degranulation
- Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
|
- Cyclosporine
- Proline
- (3r)-1-Acetyl-3-Methylpiperidine
- Ethyl Oxo(Piperidin-1-Yl)Acetate
- Sanglifehrin A
- Copper
- Artenimol
|
|